Seres Therapeutics, Inc. (MCRB)
Nasdaq: MCRB · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 2014
Who owns Seres Therapeutics, Inc.
As filed with the SECHolders of 5% or more
0
No Schedule 13D or 13G naming this company is on file.
Directors and officers
13
report now, of 31 people on the record since 2015. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 0 named at left.
Holders of 5% or moreshare of the class, as filed
Fmr LLC
SCHEDULE 13G/A · filed Aug 6, 2025 · COMMON STOCK · reported falling below 5%, from 5.7% in Jun 6, 2025
What MCRB reports owning in othersstakes of 5% or more, and other ties
Seres Therapeutics, Inc. reports no stake in another company in the record.
Insider tradesForm 4
16sales
0purchases
15sales on a scheduled plan
5people selling
$100,000sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window5 of 47 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Shaff Eric D. | CEO and President | 4 | $0 | 4 | 0 | $0 |
| Henn Matthew R. | President and Chief Scientific Officer | 4 | $0 | 4 | 0 | $0 |
| Brady Kelly | EVP, Chief Operating Officer | 2 | $0 | 1 | 0 | $0 |
| Desrosier Thomas | EVP and Chief Legal Officer | 4 | $0 | 4 | 0 | $0 |
| Young Teresa L. | EVP, Chief Commercial & Strategy Officer | 2 | $0 | 2 | 0 | $0 |